Abstract
BACKGROUND: Treat to target (T2T), aiming at inactive disease (ID), has become the recommended strategy for axial-SpA (ax-SpA). Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).
METHODS: A multicentric, cross-sectional study was performed assessing disease activity status (BASDAI and ASDAS) of consecutive patients with ax-SpA on stable treatment with TNFi for at least six months. We analyzed differences with nonradiographic axSpA (nr-ax-SpA) and the influence of population characteristics and comorbidities in reaching ID. ID was defined as ASDAS-CRP <1.3.
RESULTS: A total of 218 patients were enrolled, 165 with AS and 53 with nr-ax-SpA. ASDAS-CRP ID was reached by 89 (40.8%) patients, while 163 (74.8%) of patients achieved good disease control with BASDAI. There were no significant differences between the two diagnostic groups. Multivariate logistic regression demonstrated a negative correlation of concomitant fibromyalgia, higher BASMI and current NSAIDs with the chances of reaching ASDAS-CRP ID or BASDAI <4.
CONCLUSION: T2T represents a new challenge in the management of ax-SpA, with recently introduced disease activity measures being significantly more stringent. The prevalence of ID was affected by concomitant fibromyalgia, decreased spine mobility and concomitant NSAIDs.
| Original language | English |
|---|---|
| Pages (from-to) | 542-549 |
| Number of pages | 8 |
| Journal | Modern Rheumatology |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 2018 |
Fingerprint
Keywords
- Adult
- Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
- Female
- Fibromyalgia/epidemiology
- Humans
- Male
- Middle Aged
- Severity of Illness Index
- Spondylitis, Ankylosing/drug therapy
- Tumor Necrosis Factor-alpha/antagonists & inhibitors
Cite this
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. / Monti, Sara; Todoerti, Monica; Codullo, Veronica; Favalli, Ennio Giulio; Biggioggero, Martina; Becciolini, Andrea; Montecucco, Carlomaurizio; Caporali, Roberto.
In: Modern Rheumatology, Vol. 28, No. 3, 05.2018, p. 542-549.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors
AU - Monti, Sara
AU - Todoerti, Monica
AU - Codullo, Veronica
AU - Favalli, Ennio Giulio
AU - Biggioggero, Martina
AU - Becciolini, Andrea
AU - Montecucco, Carlomaurizio
AU - Caporali, Roberto
PY - 2018/5
Y1 - 2018/5
N2 - BACKGROUND: Treat to target (T2T), aiming at inactive disease (ID), has become the recommended strategy for axial-SpA (ax-SpA). Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).METHODS: A multicentric, cross-sectional study was performed assessing disease activity status (BASDAI and ASDAS) of consecutive patients with ax-SpA on stable treatment with TNFi for at least six months. We analyzed differences with nonradiographic axSpA (nr-ax-SpA) and the influence of population characteristics and comorbidities in reaching ID. ID was defined as ASDAS-CRP <1.3.RESULTS: A total of 218 patients were enrolled, 165 with AS and 53 with nr-ax-SpA. ASDAS-CRP ID was reached by 89 (40.8%) patients, while 163 (74.8%) of patients achieved good disease control with BASDAI. There were no significant differences between the two diagnostic groups. Multivariate logistic regression demonstrated a negative correlation of concomitant fibromyalgia, higher BASMI and current NSAIDs with the chances of reaching ASDAS-CRP ID or BASDAI <4.CONCLUSION: T2T represents a new challenge in the management of ax-SpA, with recently introduced disease activity measures being significantly more stringent. The prevalence of ID was affected by concomitant fibromyalgia, decreased spine mobility and concomitant NSAIDs.
AB - BACKGROUND: Treat to target (T2T), aiming at inactive disease (ID), has become the recommended strategy for axial-SpA (ax-SpA). Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).METHODS: A multicentric, cross-sectional study was performed assessing disease activity status (BASDAI and ASDAS) of consecutive patients with ax-SpA on stable treatment with TNFi for at least six months. We analyzed differences with nonradiographic axSpA (nr-ax-SpA) and the influence of population characteristics and comorbidities in reaching ID. ID was defined as ASDAS-CRP <1.3.RESULTS: A total of 218 patients were enrolled, 165 with AS and 53 with nr-ax-SpA. ASDAS-CRP ID was reached by 89 (40.8%) patients, while 163 (74.8%) of patients achieved good disease control with BASDAI. There were no significant differences between the two diagnostic groups. Multivariate logistic regression demonstrated a negative correlation of concomitant fibromyalgia, higher BASMI and current NSAIDs with the chances of reaching ASDAS-CRP ID or BASDAI <4.CONCLUSION: T2T represents a new challenge in the management of ax-SpA, with recently introduced disease activity measures being significantly more stringent. The prevalence of ID was affected by concomitant fibromyalgia, decreased spine mobility and concomitant NSAIDs.
KW - Adult
KW - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
KW - Female
KW - Fibromyalgia/epidemiology
KW - Humans
KW - Male
KW - Middle Aged
KW - Severity of Illness Index
KW - Spondylitis, Ankylosing/drug therapy
KW - Tumor Necrosis Factor-alpha/antagonists & inhibitors
U2 - 10.1080/14397595.2017.1367076
DO - 10.1080/14397595.2017.1367076
M3 - Article
C2 - 28880727
VL - 28
SP - 542
EP - 549
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 3
ER -